The network pharmacology study and molecular docking to investigate the potential mechanism of Acoritataninowii Rhizoma against Alzheimer's Disease

Abstract

Background and objective: Alzheimer's Disease (AD) is considered as a progressively developing neurodegenerative disease with an insidious onset that induces increased cost of social burden and decreased quality of life. Acoritataninowii Rhizoma produced the effects of resuscitating and eliminating phlegm, dispelling dampness and appetizing, refreshing mind and nourishing the mind, and exerted the activities of anti-dementia and improving learning and memory. while little was relevant to its anti-AD mechanism. The present study explored the potential mechanism of Acoritataninowii Rhizoma defend AD by network pharmacology and molecular docking.Methods: The bioactive ingredients of Acoritataninowii Rhizoma were screened by absorption, distribution, metabolism as well as excretion evaluation and obtained from databases retrieval. Genes associated with AD or ingredients were searching by databases, and the overlapping genes between AD and ingredients were analyzed by the Venn diagram. Moreover, the network of Acoritataninowii Rhizoma-ingredients-targets-AD was visualized by cytoscape software. Furthermore, protein-protein interaction, gene ontology, pathway enrichment and molecular docking were conducted to evaluate potential factors of Acoritataninowii Rhizoma against AD.Results: 4 potential compounds were considered as bioactive ingredients after screening ADME. 81 ingredients-related genes and 6765 AD-related genes were screened by databases with 61 overlapping genes. The bioactive ingredients derived from Acoritataninowii Rhizoma (e.g Cycloartenol, (1R,3aS,4R,6aS)-1,4bis (3,4-dimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[4,3-c]furan, 8-Isopentenyl-kaempferol, kaempferol) and target proteins (e.g AKT1, JUN, ESR1, CASP3, MAPK14, RELA) with high degree in the network were associated with in mitogen-activated protein kinase (MAPK) of DNA-binding transcription factor.Moreover, Acoritataninowii Rhizoma might play a signi cant in the treatment of AD which induced Fluid shear stress and atherosclerosis, Kaposi sarcomaassociated herpesvirus infection, Epstein-Barr virus infection, AGE-RAGE signaling pathway in diabetic complications. Conclusion:The bioactive ingredients and potential mechnism of Acoritataninowii Rhizoma defended AD was analyzed by network pharmacology and molecular docking. This study provided a research basis and scienti c evidence for supporting the activities of Acoritataninowii Rhizoma against AD.

Mathematical modeling of transdermal delivery of topical drug formulations in a dynamic microfluidic diffusion chamber in health and disease

“…To simulate drug penetration and diffusion across the physiological barriers several methods have been described [1][2][3][4][5]. However, these in silico methods mainly focused on molecular docking.…”

Study on the Pharmacological Mechanism of Icariin for the Treatment of Alzheimer’s Disease Based on Network Pharmacology and Molecular Docking Techniques

“…It comprehensively explores the mechanistic actions of drugs on diseases and is currently widely employed to investigate the potential mechanisms underlying the effects of various drugs and their components on multiple diseases [ 16 , 17 , 18 ]. By adopting molecular docking techniques, the interactions between ligands and receptors can be predicted [ 19 , 20 ]. This paper aimed to screen the core targets of effective ingredients from Epimedium based on network pharmacology, and to adopt a multi-target interaction network and molecular docking techniques to investigate the main active ingredient of Epimedium ICA, identify the signaling pathways related to key targets for the treatment of AD, and explore the potential mechanisms of ICA active ingredients in the treatment of AD.…”

Network pharmacology study on fermented soybeans for the prevention of Alzheimer's disease in older individuals

“…At present, the main drugs for preventing AD are acetylcholinesterase inhibitors, glutamate receptor antagonists, and piracetam, which can alleviate AD symptoms (Qiu et al, 2023). In addition, there are other methods for preventive treatment.…”